To assess whether nonneoplastic Bcl-2/IgH rearrangements act as a confounding factor in the setting of minimal residual disease analysis by evaluating their incidence in a panel of lymphoma-free subjects, including cancer-free donors and chemotherapy-naive and chemotherapy-treated cancer patients.
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy / M. Ladetto, D. Drandi, M. Compagno, M. Astolfi, F. Volpato, C. Voena, A. Novarino, B. Pollio, A. Addeo, I. Ricca, P. Falco, F. Cavallo, S. Vallet, P. Corradini, A. Pileri, G. Tamponi, A. Palumbo, O. Bertetto, M. Boccadoro, C. Tarella. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 21:7(2003 Apr 01), pp. 1398-1403. [10.1200/JCO.2003.07.070]
PCR-detectable nonneoplastic Bcl-2/IgH rearrangements are common in normal subjects and cancer patients at diagnosis but rare in subjects treated with chemotherapy
P. Corradini;C. Tarella
2003
Abstract
To assess whether nonneoplastic Bcl-2/IgH rearrangements act as a confounding factor in the setting of minimal residual disease analysis by evaluating their incidence in a panel of lymphoma-free subjects, including cancer-free donors and chemotherapy-naive and chemotherapy-treated cancer patients.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
